It notes that in June, researchers led by the University College London's Julian Gillmore reported in the New England Journal of Medicine on their test of Intellia Therapeutics and Regeneron's CRISPR-based drug to treat transthyretin amyloidosis. The small study, as GenomeWeb reported, found treatment led to a reduction in serum TTR protein levels —TTR accumulates in transthyretin amyloidosis in nerves and the heart.
Time adds that the study's use of mRNA to deliver CRISPR machinery highlights how it could be used beyond vaccines, as the approach could be adapted beyond transthyretin amyloidosis for other diseases and conditions. "To imagine using [CRISPR] as a therapy for people, you need to figure out how to get these editing tools into the cells you're trying to fix. That's where messenger RNA comes in," Daniel Anderson from MIT and CRISPR Therapeutics, who was not involved in the research, tells Time.